Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

被引:116
作者
Fletcher, CV
Anderson, PL
Kakuda, TN
Schacker, TW
Henry, K
Gross, CR
Brundage, RC
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Expt & Clin Pharmacol, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Infect Dis, Denver, CO 80262 USA
[3] Hennepin Cty Med Ctr, HIV Program, Minneapolis, MN 55415 USA
关键词
antiretroviral therapy; combination therapy; drug concentrations; pharmacokinetics; therapeutic drug monitoring;
D O I
10.1097/00002030-200203080-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To demonstrate the feasibility of a concentration-control led approach to combination antiretroviral therapy, and to compare the virological responses and safety of this strategy versus conventional fixed-close therapy. Design: A prospective, randomized, 52 week, open-label trial of concentration-controlled compared with conventional dose zidovudine, lamivudine, and indinavir therapy conduced in a university-based general clinical research center in the United States. Patients: Forty anti retroviral-naive individuals with plasma HIV-RNA levels > 5000 copies/ml. Interventions: Zidovudine, lamivudine, and indinavir plasma concentrations were measured in all participants. Doses were adjusted in those assigned to concentration-controlled therapy to achieve levels equal to or greater than target values. Main outcome measures: The proportion of patients who achieved the desired drug concentrations, the proportion of patients with HIV-RNA levels < 50 copies/ml at week 52, and safety and tolerance in the concentration-control led versus conventional therapy arms. Results: Significantly more concentration-control led recipients achieved the desired concentration targets for all three drugs: 15 of 16 concentration-controlled recipients compared with nine of 17 conventional recipients (P = 0.017) had HIV-RNA levels < 50 copies/ml at week 52. No difference was observed in the occurrence of drug-related clinical events or laboratory abnormalities between the two treatment arms. Conclusion: Concentration-control led therapy implemented simultaneously for three antiretroviral agents was feasible, as well tolerated as conventional therapy, and resulted in a greater proportion of recipients with HlV-RNA levels < 50 copies/ml after 52 weeks. These findings provide a scientific basis to challenge the accepted practice of administering the same dose of antiretroviral agents to all adults, ignoring the concentrations actually achieved. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:551 / 560
页数:10
相关论文
共 50 条
  • [21] Natural history of HIV infection in the era of combination antiretroviral therapy
    Moore, RD
    Chaisson, RE
    AIDS, 1999, 13 (14) : 1933 - 1942
  • [22] Association of HIV Infection and Antiretroviral Therapy With Sudden Cardiac Death
    Yen, Yung-Feng
    Lai, Yun-Ju
    Chen, Yu-Yen
    Lai, Hsin-Hao
    Chuang, Pei-Hung
    Chen, Chu-Chieh
    Deng, Chung-Yeh
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (05) : 468 - 474
  • [23] Effect of Antiretroviral Therapy on Growth Parameters of Children With HIV Infection
    Seth, Anju
    Malhotra, Rajeev Kumar
    Gupta, Rohini
    Chandra, Jagdish
    Kumar, Praveen
    Singh, Sarita
    Sharma, Garima
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (01) : 85 - 89
  • [24] The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection
    Sharma, Shweta
    Schlusser, Katherine E.
    de la Torre, Pola
    Tambussi, Giuseppe
    Draenert, Rika
    Pinto, Angie N.
    Metcalf, Julia A.
    Neaton, James D.
    Laeyendecker, Oliver
    AIDS, 2019, 33 (08) : 1335 - 1344
  • [25] HIV infection and antiretroviral therapy lead to unfolded protein response activation
    Mariana Borsa
    Pedro L. C. Ferreira
    Andrea Petry
    Luiz G. E. Ferreira
    Maristela M. Camargo
    Dumith Chequer Bou-Habib
    Aguinaldo R. Pinto
    Virology Journal, 12
  • [26] Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy
    Gongvatana, Assawin
    Harezlak, Jaroslaw
    Buchthal, Steven
    Daar, Eric
    Schifitto, Giovanni
    Campbell, Thomas
    Taylor, Michael
    Singer, Elyse
    Algers, Jeffrey
    Zhong, Jianhui
    Brown, Mark
    McMahon, Deborah
    So, Yuen T.
    Mi, Deming
    Heaton, Robert
    Robertson, Kevin
    Yiannoutsos, Constantin
    Cohen, Ronald A.
    Navia, Bradford
    JOURNAL OF NEUROVIROLOGY, 2013, 19 (03) : 209 - 218
  • [27] The rise and fall of tuberculosis in Malawi: associations with HIV infection and antiretroviral therapy
    Kanyerere, Henry
    Harries, Anthony D.
    Tayler-Smith, Katie
    Jahn, Andreas
    Zachariah, Rony
    Chimbwandira, Frank M.
    Mpunga, James
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2016, 21 (01) : 101 - 107
  • [28] Taking antiretroviral therapy for HIV infection - Learning from patients' stories
    Laws, MB
    Wilson, IB
    Bowser, DM
    Kerr, SM
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2000, 15 (12) : 848 - 858
  • [29] Obstetric complications related to antiretroviral therapy in pregnant women with HIV infection
    Calvo Aleman, M.
    de la Calle, M.
    Montes Ramirez, M. L.
    Escosa Garcia, L.
    Elorza, M. D.
    Gonzalez Garcia, J.
    Bartha, J. L.
    CLINICA E INVESTIGACION EN GINECOLOGIA Y OBSTETRICIA, 2022, 49 (01):
  • [30] Comparative potency of three antiretroviral therapy regimes in primary HIV infection
    Fidler, S
    Fraser, C
    Fox, J
    Tamm, N
    Griffin, JT
    Weber, J
    AIDS, 2006, 20 (02) : 247 - 252